EU/3/17/1842

About

On 27 February 2017, orphan designation (EU/3/17/1842) was granted by the European Commission to EUDRAC Limited, United Kingdom, for recombinant human club cell 10 KDa protein for the treatment of bronchiolitis obliterans syndrome.

The sponsorship was transferred to EUDRAC GmbH, Germany, in April 2019.

Key facts

Active substance
Recombinant human club cell 10 KDa protein
Disease / condition
Treatment of bronchiolitis obliterans syndrome
Date of first decision
27/02/2017
Outcome
Positive
EU designation number
EU/3/17/1842

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product it it is approved for marketing authorisation.

Sponsor's contact details

EUDRAC GmbH
Waldhofer Str. 104
69123 Heidelberg
Germany
Tel. +49 (0) 6221 7552210
E-mail: orphan@eudrac.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating